Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where QGEN advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
QGEN moved above its 50-day moving average on August 07, 2025 date and that indicates a change from a downward trend to an upward trend.
QGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 199 cases where QGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for QGEN moved out of overbought territory on July 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on QGEN as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for QGEN turned negative on July 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.972) is normal, around the industry mean (8.160). P/E Ratio (28.155) is within average values for comparable stocks, (132.856). Projected Growth (PEG Ratio) (1.092) is also within normal values, averaging (1.738). Dividend Yield (0.005) settles around the average of (0.025) among similar stocks. P/S Ratio (5.107) is also within normal values, averaging (7.877).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of sample and assay technology products for preanalytical sample preparations
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
JHDV | 38.44 | 0.28 | +0.73% |
JHancock U.S. High Dividend ETF | |||
DUKX | 24.34 | 0.03 | +0.13% |
Ocean Park International ETF | |||
NUEM | 34.03 | N/A | N/A |
Nuveen ESG Emerging Markets Equity ETF | |||
EOCT | 28.82 | -0.03 | -0.11% |
Innovator Emerg Mkts Pwr Bffr ETF™-Oct | |||
GLTR | 142.93 | -0.27 | -0.19% |
abrdn Physical PrecMtlBsk Shrs ETF |
A.I.dvisor indicates that over the last year, QGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if QGEN jumps, then DHR could also see price increases.
Ticker / NAME | Correlation To QGEN | 1D Price Change % | ||
---|---|---|---|---|
QGEN | 100% | -0.66% | ||
DHR - QGEN | 67% Closely correlated | +1.04% | ||
RVTY - QGEN | 64% Loosely correlated | +0.44% | ||
A - QGEN | 63% Loosely correlated | +0.56% | ||
TMO - QGEN | 60% Loosely correlated | +1.32% | ||
MTD - QGEN | 60% Loosely correlated | +1.54% | ||
More |